Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. - Huls G; Chitu DA; Tick L; Boersma R; Breems D; Herbers A; Klein SK; de Jonge S; Westerweel PE; Cruijsen M; Hoogendoorn M; Cuijpers M; et al. (Annals of hematology, 2025)